Natco Pharma rights issue: ₹1,300cr terms due Sep 25

What the company has scheduled

Natco Pharma has called a board meeting for September 25, 2026 to finalise the terms of its proposed rights issue capped at ₹1,300 crore. The company has indicated that the board will decide key issue parameters such as the rights issue price, payment mechanism, entitlement ratio, record date, and the timing of the issuance. The rights issue will be made through equity shares with a face value of ₹2 each. While the fundraising cap is already approved, the final number of shares will depend on the issue price and ratio that the board fixes. The meeting is positioned as the next decision point after the company completed initial exchange-related formalities.

Rights issue size and instrument details

The company has stated that the total amount proposed to be raised through the rights issue will not exceed ₹1,300 crore, which has also been referenced as ₹13,000 million. The instrument is fully paid-up equity shares, offered on a rights basis to existing equity shareholders. Natco Pharma has clarified that the face value of each equity share under the issue will be ₹2. Beyond this, the company has not yet disclosed the issue price, the entitlement ratio, or the record date for determining eligible shareholders. Those items are specifically listed among the decisions expected from the September 25 board meeting.

Exchange approvals: a procedural milestone

Natco Pharma has received in-principle approvals from both the Bombay Stock Exchange and the National Stock Exchange for the proposed rights issue. The company said these approvals were received on September 21, 2026 and described them as a procedural milestone for the capital raise. The approvals relate to the listing of the rights equity shares on the same exchanges where Natco Pharma’s existing equity shares are already listed. The company communicated the development through a filing submitted to the respective listing departments of the exchanges. Natco Pharma also noted that copies of the approval letters are available on its investor relations website.

Trading window closure around the decision

Alongside the planned board meeting, Natco Pharma said its trading window will remain closed from September 23, 2026. The closure will continue until 48 hours after the board meeting outcome is disclosed. Trading window closures are typically linked to internal controls around unpublished price sensitive information. In this case, the company is approaching a board decision that will determine detailed terms for a capital raising event. The timeline suggests that the company intends to follow standard disclosure sequencing around the board’s final decisions.

What was approved earlier on September 9

Natco Pharma’s board had already approved the rights issue at a meeting held on September 9, 2026. At that time, the board approved a proposal to raise up to ₹1,300 crore through a rights issue of equity shares to existing shareholders. The board also approved the draft letter of offer for the rights issue. Natco Pharma indicated that the fundraising would be executed through a rights issue, replacing an earlier broader mandate that could have included equity or other securities. However, the company left the issue price, entitlement ratio, record date, and other detailed terms for later finalisation.

Committee oversight and decision framework

In disclosures linked to the September 9 decision, Natco Pharma also approved the formation of a Fund-Raising Committee. The committee was stated to comprise V.C. Nannapaneni (Chairman), Rajeev Nannapaneni (Member), and P.S.R.K. Prasad (Member). The stated purpose of the committee is to oversee the rights issue process. Even with such a committee in place, the board meeting scheduled for September 25 is expected to be central to finalising the key parameters that determine shareholder entitlements, payment structure, and execution timing.

Regulatory pathway the company cited

Natco Pharma said the issue will be carried out in accordance with applicable provisions, including the Companies Act, 2013 and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. The proposed fundraising has also been described as subject to applicable regulatory and statutory approvals. The board-approved draft letter of offer has been prepared in line with these frameworks and other applicable laws, as stated by the company. With in-principle exchange approvals already received, the remaining milestones depend on final terms, formal filings, and required disclosures.

Linkages to other corporate actions mentioned

Separately, Natco Pharma has indicated that the proposed rights issue would require changes to the planned demerger of Natco Crop Health Sciences. The scheme was said to have received observation letters from both stock exchanges but had not yet been filed with the National Company Law Tribunal. The company also stated that it would make necessary consequential changes to the scheme after completion of the rights issue to maintain the proposed share swap ratio, followed by revised filings with the stock exchanges. These references connect the fundraising to broader corporate structuring steps that remain in process.

What this means for shareholders and the stock

A rights issue, by design, is offered to existing equity shareholders, and Natco Pharma has reiterated eligibility will be based on names appearing in the company’s records as of a record date to be determined. For investors, the most material near-term information is the price, entitlement ratio, and record date, because these define how much capital shareholders can contribute and the resulting share issuance. Until these are disclosed, the ₹1,300 crore cap functions mainly as an upper limit rather than a final issuance number. The in-principle approvals from BSE and NSE indicate that the company has progressed through an important exchange step, but the detailed economic terms remain pending. Natco Pharma’s trading window closure also signals the company’s proximity to decisions that could influence market-sensitive expectations.

Key facts at a glance

What to watch after September 25

After the September 25 board meeting, investors will look for the company’s disclosure on the rights issue price, entitlement ratio, record date, and the timetable for subscription and allotment. Those disclosures will determine the final number of shares to be issued under the ₹1,300 crore cap. Natco Pharma has also indicated that copies of exchange approval letters are hosted on its investor relations website, which may be used by investors tracking procedural progress. In addition, any update on adjustments to the Natco Crop Health Sciences demerger scheme, referenced as requiring changes due to the rights issue, will be closely tied to the sequencing of these corporate actions.

Conclusion

Natco Pharma’s rights issue has moved from board approval on September 9 to exchange in-principle approvals on September 21, and now to a September 25 board meeting focused on final terms. The company has already fixed the cap at ₹1,300 crore and confirmed equity shares of face value ₹2, but has yet to disclose the economic and operational details that determine shareholder eligibility and issuance size. The next confirmed step is the board’s decision on pricing, entitlement ratio, record date, and the issue timetable, followed by the company’s formal disclosures after the meeting outcome is announced.